Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24647
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
max_severity (max_severity)
Data file: SHERPA_Safetydata
Overview
Valid:
343
Invalid:
0
Type:
Discrete
Width:
48
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| Asymptomatic | 285 |
83.1%
|
|
| Mild symptoms (able to do most daily functions) | 54 |
15.7%
|
|
| Moderate (struggling with daily functions) | 3 |
0.9%
|
|
| Severe (requiring oxygen and/or hospitalization) | 1 |
0.3%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.